See the DrugPatentWatch profile for tigecycline

The extension of the tigecycline injection patent can offer several benefits. Tigecycline is an antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, and community-acquired pneumonia [1]. The additional time provided by the patent extension can have positive effects on different stakeholders, including the manufacturer, healthcare providers, and patients.

1. **Revenue and Investment**: The patent extension grants the manufacturer, Wyeth Pharmaceuticals, exclusive rights to produce and sell tigecycline injections for a more extended period. This exclusivity can lead to increased revenue, which can be invested in research and development of new pharmaceutical products [1].

2. **Market Stability**: An extended patent can provide market stability by preventing generic competition. This stability allows the manufacturer to maintain consistent pricing, which can be crucial for hospitals and healthcare providers that rely on tigecycline for treating patients [1].

3. **Quality Assurance**: Exclusive production rights enable the manufacturer to maintain strict quality control over the drug's production. This can lead to more consistent product quality and potentially reduce the risk of adverse events or medication errors [1].

4. **Patient Access**: The revenue generated from the patent extension can be used to support patient assistance programs, ensuring that patients have continued access to tigecycline during and after the patent period [1].

It is important to note that while patent extensions can offer benefits, they can also lead to higher drug prices and potential barriers to access for some patients [1].

Sources:
[1] DrugPatentWatch.com - Tigecycline Hydrochloride Point-of-Care Drug Profile. <https://drugpatentwatch.com/drugs/tigecycline-hydrochloride>